GreenLight Biosciences, Inc.
200 Boston Avenue
Suite 1000
Medford
Massachusetts
02155
United States
Tel: 617-716-7777
56 articles about GreenLight Biosciences, Inc.
-
GreenLight Biosciences Secures EPA Registration for New Bioinsecticide, Calantha, Historic Step Towards A Safer and More Sustainable Food System
1/4/2024
GreenLight Biosciences (GreenLight Bio) has been granted registration by the U.S. Environmental Protection Agency (EPA) and several states for its groundbreaking Calantha™ product, designed to target and control the highly destructive Colorado potato beetle.
-
GreenLight Announces Completion of Merger with Fall Line Endurance Fund
7/24/2023
GreenLight Biosciences Holdings, PBC announced the closing of its previously announced merger with SW MergerCo, Inc. and SW ParentCo, Inc., pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent.
-
GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares
7/20/2023
GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. (“Merger Sub”) and SW ParentCo, Inc (“Parent”).
-
GreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
5/11/2023
GreenLight Biosciences, PBC, a biotechnology company dedicated to making RNA products affordable and accessible for human health and agriculture, reported operational highlights and financial results for the first quarter ended March 31, 2023.
-
GreenLight Biosciences Releases Inaugural Sustainability Report
4/12/2023
GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today released its inaugural Sustainability Report.
-
GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line
3/30/2023
GreenLight Biosciences confirmed that it has received a non-binding indication of interest from Fall Line Endurance Fund, L.P. to acquire all of the outstanding capital stock of the Company for $0.60 per share in cash.
-
GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results
3/28/2023
GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today reported operational highlights and financial results for the fourth quarter and full year ended December 31, 2022.
-
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D Day
3/9/2023
GreenLight Biosciences will today outline its pipeline strategy and R&D progress for mRNA-based solutions during its Human Health R&D Day being held today, March 9, 2023 at 10:30 a.m. ET in Lexington, MA.
-
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D Day
3/7/2023
GreenLight Biosciences will outline its pipeline strategy and R&D progress for dsRNA based crop protection and plant delivery innovations focused on addressing food security with innovative and sustainable solutions during its Plant Health R&D Day being held today, March 7th, 2023 at 10:30 a.m. ET in Research Triangle, North Carolina.
-
GreenLight Biosciences to Host R&D Day Series on Plant and Human Health Development Strategy
3/1/2023
GreenLight Biosciences, a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, announced it will host a two-part R&D Day Series for analysts and investors.
-
GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate
2/1/2023
GreenLight Biosciences today announced that it has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a Phase I/II clinical trial of its vaccine candidate against Covid-19, as a booster to previously vaccinated individuals. Preparations for the trial are underway.
-
GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines
1/9/2023
GreenLight Biosciences Holdings, PBC (Nasdaq:GRNA), and EpiVax Therapeutics Inc, today announced that they have signed an exclusive collaboration agreement to jointly develop and commercialize personalized mRNA-based vaccine candidates for cancers.
-
GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
11/9/2022
GreenLight Biosciences Holdings, PBC today reported operational highlights and financial results for the third quarter ended September 30, 2022.
-
GreenLight Biosciences to Participate in Upcoming Investor Conferences in November 2022
11/7/2022
GreenLight Biosciences announced that Dr. Andrey Zarur, CEO, and Susan Keefe, CFO will participate in two upcoming investor conferences in November.
-
As part of a realignment, GreenLight Biosciences is cutting staff by about 25%, the company announced Wednesday.
-
GreenLight Biosciences announces realignment to focus on near-term value drivers
10/12/2022
GreenLight Biosciences announced a realignment to focus on key near-term value drivers and extend its cash runway.
-
GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA
10/5/2022
GreenLight Biosciences and Queensland University of Technology (QUT) partner to create a solution for fall armyworm.
-
GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
8/15/2022
GreenLight Biosciences today reported operational highlights and financial results for the second quarter ended June 30, 2022.
-
CRISPR Therapeutics, Clovis Oncology and VistaGen all released Q2 results this week, while GreenLight Biosciences has some extra cash to work with.
-
GreenLight Biosciences announces $109 million financing
8/12/2022
GreenLight Biosciences today announced a private placement of approximately $109 million.